Fig. 5: CuET efficiently kills CD319+/CD138+ MM cancer cells isolated from patients independently of disease stage and ongoing/passed therapy. | Cell Death & Disease

Fig. 5: CuET efficiently kills CD319+/CD138+ MM cancer cells isolated from patients independently of disease stage and ongoing/passed therapy.

From: A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment

Fig. 5

A Cytotoxic effect of CuET in a patient diagnosed for Monoclonal gammopathy of undetermined significance (MGUS; asymptomatic Multiple Myeloma). B Cytotoxic effect of CuET in a patient newly diagnosed with Multiple Myeloma without any passed therapy. C Cytotoxic effect of CuET in a patient diagnosed with Multiple Myeloma under Bortezomib therapy. D Cytotoxic effect of CuET in relapsed Multiple Myeloma patients after two years in remission. E Cytotoxic effect of CuET in a patient been in progression phase of the disease after a remission. F Cytotoxic effect of CuET in Multiple Myeloma patients being resistant to all available anti-MM therapies (proteasome inhibitors and immunomodulatory drugs). Each graph represents a single patient, samples treated for 24 h.

Back to article page